Wang Li-Juan, Wu Hu-Bing, Wang Meng, Han Yan-Jiang, Li Hong-Sheng, Zhou Wen-Lan, Wang Quan-Shi
NanFang PET/CT Center, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, Guangdong Province 510515, China.
Eur J Radiol. 2015 Nov;84(11):2275-9. doi: 10.1016/j.ejrad.2015.09.011. Epub 2015 Sep 11.
Primary bone lymphoma (PBL) is a rare type of malignant lymphoma. Few data have been reported regarding the utility of F-18 FDG PET/CT in this disease. The aim of this study was to assess the role of F-18 FDG PET/CT in the diagnosis and therapeutic effect evaluation of PBL.
A total of 19 consecutive patients with PBL were enrolled. Whole-body PET/CT scan was performed for all patients. The diagnosis of PBL was established by histopathology and immunohistochemistry.
F-18 FDG PET/CT was positive in 94.7% (18/19) of patients. Uptake of FDG in lesions was intense with SUVmax of 15.14 ± 11.82. Multiple involved lesions were found in 47.4% (9/19) patients, while 52.6% presented with a single involved lesion. Based on the lesions, PET detected 98.9% (87/88) lesions. Among them, 71.6% (63/88) lesions were found to be located in axial skeleton and 28.4% (25/88) in the extremity skeleton. FDG PET/CT also found the lesions infiltrate to the surrounding soft tissue in 84.2% (16/19) patients. On the syn-modality CT, the bone destruction was noted in 43.2% (38/88) of the lesions, of which 50.0% lesions presented as slight change in bone density and 50.0% as severe change. The diagnostic sensitivity of PET was much higher than that of CT (98.9% vs. 43.2%, P=0.000). PET/CT was performed for evaluation of treatment response in 13 patients. In 12 patients with complete response(CR), PET/CT found the 25 lesions were F-18 FDG fully resoluted after treatment, however, bone destruction was still presented in 72.0% (18/25) lesions.
The present study suggests that F-18 FDG PET/CT was a sensitive imaging modality for diagnosis and treatment response evaluation of PBL.
原发性骨淋巴瘤(PBL)是一种罕见的恶性淋巴瘤类型。关于F-18 FDG PET/CT在该疾病中的应用,报道的数据较少。本研究的目的是评估F-18 FDG PET/CT在PBL诊断及治疗效果评估中的作用。
连续纳入19例PBL患者。对所有患者进行全身PET/CT扫描。PBL的诊断通过组织病理学和免疫组织化学确定。
F-18 FDG PET/CT在94.7%(18/19)的患者中呈阳性。病变部位FDG摄取强烈,SUVmax为15.14±11.82。47.4%(9/19)的患者发现有多个受累病变,而52.6%的患者表现为单个受累病变。基于病变,PET检测到98.9%(87/88)的病变。其中,71.6%(63/88)的病变位于中轴骨骼,28.4%(25/88)位于四肢骨骼。FDG PET/CT还发现84.2%(16/19)的患者病变浸润至周围软组织。在同机CT上,43.2%(38/88)的病变存在骨质破坏,其中50.0%的病变表现为骨密度轻度改变,50.0%表现为重度改变。PET的诊断敏感性远高于CT(98.9%对43.2%,P=0.000)。对13例患者进行PET/CT评估治疗反应。在12例完全缓解(CR)的患者中,PET/CT发现治疗后25个病变的F-18 FDG完全消退,但72.0%(18/25)的病变仍存在骨质破坏。
本研究表明,F-18 FDG PET/CT是PBL诊断及治疗反应评估的一种敏感成像方式。